

*Handbook of*  
*Psychopharmacology*

---

Volume 2  
Principles of Receptor Research

# *Handbook of Psychopharmacology*

## SECTION I: BASIC NEUROPHARMACOLOGY

- Volume 1 Biochemical Principles and Techniques in Neuropharmacology
- Volume 2 Principles of Receptor Research
- Volume 3 Biochemistry of Biogenic Amines
- Volume 4 Amino Acid Neurotransmitters
- Volume 5 Synaptic Modulators
- Volume 6 Biogenic Amine Receptors

*in preparation*

## SECTION II: BEHAVIORAL PHARMACOLOGY IN ANIMALS

## SECTION III: HUMAN PSYCHOPHARMACOLOGY

Volume 2  
Principles of Receptor Research

*Edited by*

*Leslie L. Iversen*  
*Department of Pharmacology*  
*University of Cambridge*

*Susan D. Iversen*  
*Department of Psychology*  
*University of Cambridge*

*and*

*Solomon H. Snyder*  
*Departments of Pharmacology and Psychiatry*  
*The Johns Hopkins University*  
*School of Medicine*

PLENUM PRESS • NEW YORK AND LONDON

---

Library of Congress Cataloging in Publication Data

Main entry under title:

Handbook of psychopharmacology.

Includes bibliographies and indexes.

CONTENTS: v. 1. Biochemical principles and techniques in neuropharmacology.—v. 2. Principles of receptor research.—v. 3. Biochemistry of biogenic amines.—v. 4. Amino acid neurotransmitters.

1. Psychopharmacology. I. Iversen, Leslie Lars. II. Iversen, Susan D., 1940-  
III. Snyder, Solomon H., 1938- [DNLM: 1. Psychopharmacology.

QV77 H236]

RC483.H36

615'.78

75-6851

ISBN 978-1-4684-3170-4

ISBN 978-1-4684-3168-1 (eBook)

DOI 10.1007/978-1-4684-3168-1

---

© 1975 Plenum Press, New York

Softcover reprint of the hardcover 1st edition 1975

A Division of Plenum Publishing Corporation

227 West 17th Street, New York, N.Y. 10011

United Kingdom edition published by Plenum Press, London

A Division of Plenum Publishing Company, Ltd.

Davis House (4th Floor), 8 Scrubs Lane, Harlesden, London, NW10 6SE, England

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher

## CONTRIBUTORS TO VOLUME 2

- P. CUATRECASAS, *Department of Pharmacology and Experimental Therapeutics and Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland*
- M. D. HOLLENBERG, *Department of Pharmacology and Experimental Therapeutics and Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland*
- A. S. HORN, *MRC Neurochemical Pharmacology Unit, Department of Pharmacology, University of Cambridge, Cambridge, England*
- JOHN S. KELLY, *MRC Neurochemical Pharmacology Unit, Department of Pharmacology, Medical School, Cambridge University, Cambridge, England*
- S. Z. LANGER, *Instituto de Investigaciones Farmacológicas, Consejo Nacional de Investigaciones, Científicas y Técnicas, Buenos Aires, Argentina*
- BRIAN MELDRUM, *Department of Neurology, Institute of Psychiatry, London, England*
- R. D. MYERS, *Laboratory of Neuropsychology, Purdue University, Lafayette, Indiana*
- PHILLIP G. NELSON, *Behavioral Biology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland*
- BRUCE R. RANSOM, *Behavioral Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland*

# CONTENTS

## CHAPTER 1

### Blood–Brain Barrier: Techniques for the Intracerebral Administration of Drugs

R. D. MYERS

1. Introduction .....	1
2. Characteristics of the Blood–Brain Barrier .....	2
2.1. Specific Activity of the Blood–Brain Barrier .....	4
2.2. Breakdown of the Blood-Brain Barrier .....	6
2.3. The Brain–CSF Barrier .....	7
3. Bypassing the Blood–Brain Barrier: Principles .....	8
4. Pharmacological Approach to the Internal or External Surface of the Brain .....	10
4.1. Drugs Applied to the Surface of the Cortex .....	11
4.2. Administration of a Drug into the Cerebral Ventricles .....	12
4.3. Perfusion of Brain Surfaces .....	14
5. Drugs Administered to the Brain Parenchyma .....	18
5.1. Injection of Solution .....	18
5.2. Depositing a Chemical in Crystalline Form .....	21
5.3. Isolated Perfusion with Push–Pull Cannulae .....	22
6. Concluding Comment .....	24
7. References .....	25

## CHAPTER 2

### Microiontophoretic Application of Drugs onto Single Neurons

JOHN S. KELLY

1. Introduction .....	29
-----------------------	----

2. Basic Principles .....	31
2.1. Spontaneous Efflux of Active Material from Microelectrodes .....	31
2.2. Release of Ionized Substances During Passage of Iontophoretic Current .....	41
2.3. Electro-osmosis .....	46
2.4. Microinjection .....	47
3. Dispersal of Iontophoretically Applied Substances Within the Brain .....	49
3.1. Theoretical Curves Based on Models of Diffusion ....	50
3.2. Tissue Uptake Mechanisms and Drug Redistribution .....	60
4. Conclusions .....	63
5. References .....	64

### CHAPTER 3

#### Electrical Recording of Brain Activity: The EEG and Its Value in Assessing Drug Effects

BRIAN MELDRUM

1. Introduction .....	69
2. Selection of Animal Species .....	70
3. Acute Experiments .....	71
4. Chronic Implantation of Electrodes .....	72
5. Recording Procedures .....	73
5.1. Experiments in Animals with Chronic Implants .....	73
5.2. Human Studies .....	74
5.3. Derivations .....	74
5.4. Amplifiers .....	74
5.5. Paper Records .....	75
5.6. Magnetic Tape Recording .....	75
6. Methods of Analyzing and Quantifying the EEG .....	76
6.1. Hand Analysis .....	76
6.2. Integration .....	77
6.3. Frequency Analysis .....	77
6.4. Spectral Analysis .....	78
6.5. Correlation Procedures .....	78
7. Sensory Evoked Response Analysis .....	79
7.1. Visual Evoked Responses .....	80
7.2. Somatosensory Evoked Responses .....	80
7.3. Auditory Evoked Responses .....	80

8. Focal Electrical Stimulation . . . . .	81
9. Electrogenesis of the EEG and Evoked Potentials . . . . .	82
10. Assessment of Alertness, Sedation, and the Stages of Sleep . . . . .	84
11. Study of Sleep Patterns . . . . .	85
12. Abnormal EEG Records . . . . .	86
12.1. Normal Rhythms Occurring Abnormally . . . . .	86
12.2. Nonepileptic Abnormal Rhythms . . . . .	87
12.3. Epileptic Features . . . . .	87
13. Transmitters and EEG Changes . . . . .	88
13.1. Acetylcholine . . . . .	88
13.2. Catecholamines . . . . .	89
13.3. 5-Hydroxytryptamine . . . . .	91
13.4. $\gamma$ -Aminobutyric Acid . . . . .	91
14. Uses and Limitations of Macroelectrode Recordings . . . . .	92
15. References . . . . .	93

## CHAPTER 4

## Neuropharmacological Responses from Nerve Cells in Tissue Culture

BRUCE R. RANSOM AND PHILLIP G. NELSON

1. Introduction . . . . .	101
2. Muscle . . . . .	102
3. Continuous Cell Lines . . . . .	105
4. Glia . . . . .	105
5. Explants . . . . .	106
6. Dissociated Primary Cell Cultures . . . . .	108
7. Discussion . . . . .	123
8. References . . . . .	125

## CHAPTER 5

## Biochemical Identification of Membrane Receptors: Principles and Techniques

M. D. HOLLENBERG AND P. CUATRECASAS

1. Introduction . . . . .	129
2. Properties of Receptor Interactions and Technical Considerations . . . . .	131
2.1. Number and Affinity of Membrane Receptors . . . . .	131
2.2. Preparation of Radioactive Ligand Derivatives . . . . .	132



2.3.	Rates of Association and Dissociation . . . . .	135
2.4.	Competitive Antagonists as Tools for Binding Studies . . . . .	135
2.5.	The Problem of Specific vs. Nonspecific Binding . . .	136
2.6.	Methods of Obtaining Binding Data . . . . .	137
2.7.	Measurements on Solubilized Receptors . . . . .	138
2.8.	Membrane Receptors and Proteolytic Agents . . . . .	139
2.9.	Comparative Studies of Ligand–Membrane Interactions . . . . .	139
2.10.	Other Methods for the Study of Ligand–Receptor Interactions . . . . .	140
2.11.	Mathematical Analysis of Binding Data . . . . .	141
3.	Examples of Studies on Hormone–Membrane Receptor Interactions . . . . .	142
3.1.	Insulin–Receptor Interaction in Fat and Liver Cells . .	142
3.2.	Insulin Receptors in Human Lymphocytes and Fibroblasts . . . . .	146
3.3.	Insulin-like Activity and Binding of Plant Lectins . . .	153
3.4.	Glucagon Binding and Action in Liver Membranes . . .	157
3.5.	Epidermal Growth Factor Receptors in Human Fibroblasts . . . . .	160
3.6.	Catecholamine Binding and $\beta$ -Adrenergic Receptors . . . . .	161
3.7.	Macromolecular Hormone Derivatives and Plasma Membrane Receptors . . . . .	167
4.	Conclusions . . . . .	170
5.	References . . . . .	170

## CHAPTER 6

### Structure–Activity Relations for Neurotransmitter Receptor Agonists and Antagonists

A. S. HORN

1.	Introduction . . . . .	179
2.	Norepinephrine . . . . .	181
2.1.	Peripheral Nervous System . . . . .	181
2.2.	Adrenergic Receptors in the CNS . . . . .	188
2.3.	Possible Modes of Action . . . . .	189
2.4.	Crystallographic, NMR, and Theoretical Studies of the Conformation of NE . . . . .	191
3.	Dopamine . . . . .	191
3.1.	Dopamine Receptors in the Mammalian Peripheral and Central Nervous Systems . . . . .	191

3.2. Dopamine Receptors in Invertebrates . . . . .	192
3.3. Structure–Activity Relationships of DA Receptor Agonists and Antagonists in the Mammalian Peripheral Nervous System . . . . .	192
3.4. Structure–Activity Relationships of DA Receptor Agonists and Antagonists in Invertebrates . . . . .	192
3.5. DA Receptor Agonists and Antagonists in the Mammalian CNS . . . . .	193
4. 5-Hydroxytryptamine . . . . .	208
4.1. 5-HT Receptors in the Mammalian Peripheral Nervous System and Other Preparations . . . . .	208
4.2. Structure–Activity Relationships of 5-HT Agonists . . .	209
4.3. 5-HT Antagonists . . . . .	213
5. Acetylcholine . . . . .	213
5.1. Muscarinic Actions of ACh . . . . .	214
5.2. Nicotinic Actions of ACh . . . . .	214
5.3. Cholinergic Agonists . . . . .	215
5.4. Antagonists at the Nicotinic Receptor . . . . .	220
5.5. Possible Modes of Action . . . . .	223
5.6. NMR Studies . . . . .	223
5.7. Theoretical Studies . . . . .	224
5.8. X-Ray Crystallographic Studies . . . . .	224
6. Histamine . . . . .	226
6.1. Physiological Effects . . . . .	226
6.2. Histamine Receptors . . . . .	226
6.3. Structure–Activity Relationships . . . . .	227
6.4. Structure–Activity Relationships for Histamine-like Activity on Gastric Acid Secretion and Inhibition of the Rat Uterus . . . . .	228
6.5. Structure–Activity Relationships of Antihistamines . . .	229
6.6. Possible Mechanisms of Action . . . . .	230
7. References . . . . .	231

## CHAPTER 7

## Denervation Supersensitivity

S. Z. LANGER

1. Introduction . . . . .	245
2. Quantitative Methods in the Study of Supersensitivity . . . . .	246
3. Surgical and Pharmacological Denervation . . . . .	251
4. Supersensitivity After Denervation of Sympathetically Innervated Organs . . . . .	253
4.1. Events During Degeneration of Adrenergic Nerves . .	253

4.2. Prejunctional Component of Denervation Supersensitivity .....	258
4.3. Postjunctional Component of Denervation Supersensitivity .....	261
5. Supersensitivity After Denervation of Cholinergically Innervated Organs .....	265
5.1. Events During Degeneration of Cholinergic Nerves ..	265
5.2. Time Course of Development of Supersensitivity and Pharmacological Characteristics .....	267
6. Supersensitivity in the Central Nervous System .....	269
7. Clinical Implications of Supersensitivity and Subsensitivity .....	270
8. References .....	272
Index .....	281